49 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
30 Mar 18
License for the Clinical Stage Compound CTP-499 and Plans to Develop
12:00am
, Inc.
CTP-499 is an analog of an active metabolite of an approved drug and has multiple pharmacological targets that can be used to its advantage … need conditions. In these conditions, preliminary clinical evidence already exists demonstrating that affecting the multiple pharmacological targets
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
4 Aug 22
Regulation FD Disclosure
9:30am
metabolite of pentoxifylline (PTX or Trental®). PCS499 and its active metabolites have a diverse pharmacology profile and can act on multiple targets
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
18 May 23
Regulation FD Disclosure
3:24pm
that there are significant advantages to treating patients with our NGC drugs over both existing chemotherapy and oncology drugs directed toward new targets or new
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
, and targets major milestones in the second half of 2021
HANOVER, Md., August 12, 2021 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage
10-Q
yiibvqrsar
8 Aug 13
Quarterly report
12:00am
424B3
teejmfo2
6 Jun 13
Prospectus supplement
12:00am
10-K
ict2yd988j204dj zg2
27 Mar 14
Annual report
12:00am